Form 8-K Altimmune, Inc. For: May 17

May 17, 2021 7:06 AM EDT

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 17, 2021

 

ALTIMMUNE, INC.

(Exact name of registrant as specified in its charter)

 

 

 

 

 

 

Delaware

 

001-32587

 

20-2726770

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

 

 

 

 

910 Clopper Road, Suite 201S

Gaithersburg, Maryland

 

 

 

20878

(Address of principal executive offices)

 

 

 

(Zip Code)

 

 

 

 

 

Registrant’s telephone number including area code: (240) 654-1450

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common stock, par value $0.0001 per share

ALT

The NASDAQ Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

 



 

 

Item 2.02

Results of Operations and Financial Condition

On May 17, 2021, Altimmune, Inc. (the “Company”) issued a press release announcing the Company’s financial results for its fiscal quarter ended March 31, 2021. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

A copy of the presentation that will be used during the conference call presenting the Company’s financial results for the quarter ended March 31, 2021 is furnished as Exhibit 99.2 to this Current Report on Form 8-K.

The information included in this Current Report on Form 8-K (including Exhibits 99.1 and 99.2 hereto) that is furnished pursuant to this Item 2.02 shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. In addition, the information included in this Current Report on Form 8-K (including Exhibits 99.1 and 99.2 hereto) that is furnished pursuant to this Item 2.02 shall not be incorporated by reference into any filing of the Registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference into such filing.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

 


 

 

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

ALTIMMUNE, INC.

 

 

By:

 

/s/ Will Brown

 

 

Name: Will Brown

 

 

Title: Chief Financial Officer

Dated May 17, 2021

 

 

Exhibit 99.1

 

Altimmune Announces First Quarter 2021 Financial Results

and Provides a Corporate Update

 

Data Readouts from Phase 1 AdCOVID™ and ALT-801 Clinical Trials Expected in June

 

      Approximately $227 Million in Cash and Short-Term Investments to Advance Pipeline

 

 

GAITHERSBURG, MD, -- May 17, 2021 -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three months ending March 31, 2021 and provided a corporate update.

 

“With AdCOVID™, our single-dose intranasal vaccine candidate for COVID-19 and ALT-801, our GLP-1/glucagon dual agonist candidate for non-alcoholic steatohepatitis (NASH) now advancing in the clinic, 2021 has the potential to be a data-rich period for the Company,” remarked Vipin K. Garg, Ph.D., President and Chief Executive Officer at Altimmune. “We anticipate data readouts from both of these clinical trials in June. If the data from the AdCOVID Phase 1 trial are positive, we plan to quickly transition into a comprehensive global Phase 2 clinical development program. We strongly believe that a vaccine candidate like AdCOVID, which can be administered via a simple nasal spray along with what we hope will be an excellent safety and tolerability profile, could become an important tool for the global COVID-19 vaccination effort.”

 

Dr. Garg continued, “ALT-801 is also progressing as planned through its first-in-human clinical trial in Australia and we anticipate 6-week data to be available later this quarter. We are excited about the potential of ALT-801, and hope that clinical studies will show ALT-801 can deliver similar therapeutic benefits to current GLP-1 based treatment options in development but without the GI intolerability that leads to treatment discontinuation. The NASH opportunity, together with a potential indication in obesity, could be very large for ALT-801 and early clinical success could have a dramatic effect on Altimmune’s growth.”

 

Recent Highlights:

 

AdCOVID, a novel, needle-free, intranasal vaccine candidate for COVID-19

 

Enrollment target met in amended AdCOVID Phase 1 clinical trial evaluating the safety and immunogenicity of AdCOVID in healthy volunteers

 

 

o

The Phase 1 trial will measure systemic antibody responses including serum neutralizing antibody, T cell responses and mucosal IgA, a measure of mucosal immunity in the nasopharyngeal cavity


 

 

o

The study protocol was amended to reduce the number of adult subjects to approximately 80. The amendment was necessary due to the widespread availability of authorized vaccines. The final sample size of the study is comparable to the number of participants in Phase 1 studies of the U.S. authorized vaccines

 

o

A topline data readout is anticipated in June 2021

 

Progressed development of adapted AdCOVID vaccine candidates targeting emerging SARS-CoV-2 variants

 

 

o

Initiated preclinical evaluation of AdCOVID vaccine candidates targeting E484K variants, including P.1, B.1.351 and B.1.617

 

o

Initiation of a Phase 2 trial with a variant AdCOVID vaccine candidate expected in Q4 2021

 

Expanded manufacturing capabilities through an agreement with Lonza to commission a dedicated manufacturing suite for clinical and potential future commercial supply

 

 

o

Complements and extends existing network of strategic manufacturing partners, building extra capacity and redundancy into the AdCOVID manufacturing effort

 

o

Supports manufacturing of clinical supply material for potential late-stage clinical trials and commercial scale

 

Announced new data from preclinical studies conducted in collaboration with the University of Alabama at Birmingham (UAB)

In these preclinical studies, a single intranasal dose of AdCOVID provided:  

 

o

100% protection against a lethal challenge from the SARS-CoV-2 virus, with 1000-fold reduction of replicating virus in the nasal cavity and respiratory tract following infection with SARS-CoV-2

 

o

Sterilizing immunity, i.e., undetectable levels of infectious virus in the lungs, believed to be essential to fully block viral transmission

 

o

Long-lived systemic and mucosal immune responses, which were essentially unchanged over 6 months  

 

Established plans for a robust Phase 2 clinical development program, which is anticipated to include:

 

 

o

A multi-national study in adults 18 years of age and older in regions where vaccine access has been limited

 

o

An evaluation of AdCOVID as a potential booster for previously-infected and vaccinated individuals using a parental and P.1 variant AdCOVID vaccine

 

o

An age-based de-escalation study in children and adolescents

 

o

A study evaluating safety and immunogenicity in mother-infant pairs

ALT-801, a novel GLP-1/glucagon dual agonist candidate for NASH

 

Progressed ongoing Phase 1 clinical trial of ALT-801 in Australia

 


 

 

 

o

Completed enrollment in the single ascending dose (SAD) phase and 3 planned cohorts of multiple ascending dose (MAD) phase of the trial, with 6-week data anticipated in June 2021, and 12-week data anticipated in Q3 2021

 

o

Plans to commence a 52-week, Phase 2, biopsy-trial based on NASH endpoints in early 2022

 

o

Anticipated mid-year IND filing to initiate U.S. NASH studies

 

Potential filing of a second IND for an obesity indication in 2H 2021

 

 

o

The filing of a second IND in obesity in 2H 2021 is being evaluated, with the final decision based on the weight loss data from the upcoming Phase 1 trial readout

 

Other programs

 

Continued progress in Phase 1/2 clinical trial of T-COVID, a therapeutic candidate for the treatment of SARS-CoV-2 and other respiratory infections, and a Phase 2 clinical trial of HepTcell, an immunotherapeutic candidate for the treatment of chronic hepatitis B

 

 

Financial Results for the Three Months Ended March 31, 2021

 

Altimmune had cash, cash equivalents and short-term investments totaling $226.5 million at March 31, 2021 compared to $216.0 million at December 31, 2020. The increase is primarily attributable to $34.2 million of net receipts during the quarter due to its utilization of the at-the-market offering program, partially offset by $19.6 million of cash used for operating activities.

Revenue was $0.8 million for the three months ended March 31, 2021 compared to $2.2 million in the prior period, a decrease of $1.4 million. The change in revenue quarter over quarter was primarily due to a decrease of $2.0 million in BARDA revenue during the current period due to the timing of clinical trials and development activities for NasoShield, partially offset by $0.5 million in revenue attributable to T-COVID.

Research and development expenses were $11.9 million for the three months ended March 31, 2021, compared to $7.2 million in the prior period, representing an increase of $4.7 million. The change was primarily the result of increased expenses of $5.4 million related to development activities for the Company’s COVID-19 programs, partially offset by a decrease of $1.5 million resulting from a decrease in the fair value of contingent consideration liability connected with the acquisition and development of ALT-801.

General and administrative expenses were $3.8 million for the three months ended March 31, 2021 compared to $2.3 million in the prior period, an increase of $1.5 million. The increase during the quarter is primarily due to increased stock compensation expense and additional labor related costs.

Net loss for the three months ended March 31, 2021 was $14.9 million, or $0.38 net loss per share, compared to $3.9 million in the prior period, or $0.26 net loss per share. The difference in net loss is primarily attributable to higher research and development expenses and general and administrative expenses.


 

Conference Call Information

 

Date:

Monday, May 17, 2021

Time:

8:30 am Eastern Time

Domestic Dial-in:

877-423-9813

International Dial-in:

201-689-8573

Conference ID:

13719206

Webcast:

http://public.viavid.com/index.php?id=144634

 

Following the conclusion of the call, the webcast will be available for replay on the Investor Relations page of the Company’s website at www.altimmune.com. The company has used, and intends to continue to use, the IR portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD.

 

About Altimmune

 

Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit www.altimmune.com.

 

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on
Twitter

Forward-Looking Statement

 

Any statements made in this press release relating to future financial or business performance, conditions, plans, prospects, trends, or strategies and other financial and business matters, including without limitation, the timing of key milestones for our clinical assets, the timing of the data readout from the AdCOVID Phase 1 clinical trial in June 2021, the potential start of the AdCOVID Phase 2 clinical program in Q2 2021, the potential immunization effects of AdCOVID, the potential of AdCOVID to block SARS-CoV-2 transmission, the shipping and storage requirements for AdCOVID, our ability to manufacture AdCOVID for our clinical trials and commercial needs, the expected completion of the single ascending dose (SAD) and multiple ascending dose (MAD) phases of the ALT-801 study, with 6-week data expected in June 2021 and 12-week data in Q3 2021, the anticipated mid-year IND filing for ALT-801, the commencement of a 52-week, Phase 2, biopsy-trial based on NASH endpoints in early 2022, the HepTcell Phase 2 clinical efficacy trial data readout anticipated in 1H 2022, the prospects for regulatory approval of our product candidates and commercializing or selling any product or drug candidates, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to Altimmune,


 

Inc. (the “Company”) may identify forward-looking statements. The Company cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. Important factors that may cause actual results to differ materially from the results discussed in the forward looking statements or historical experience include risks and uncertainties, including risks relating to: potential impacts due to the COVID-19 pandemic such as delays in regulatory review, manufacturing and supply chain interruptions, access to clinical sites, enrollment, adverse effects on healthcare systems and disruption of the global economy; the reliability of the results of studies relating to human safety and possible adverse effects resulting from the administration of the Company’s product candidates; the Company’s ability to manufacture clinical trial materials and commercial supply on the timelines anticipated; the Company’s ability to secure manufacturing approval from its SARS-CoV-2 cell licensor on the timelines anticipated; and the success of future product advancements, including the success of future clinical trials. Further information on the factors and risks that could affect the Company's business, financial conditions and results of operations are contained in the Company’s filings with the U.S. Securities and Exchange Commission, including under the heading “Risk Factors” in the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2020 filed with the SEC, which is available at www.sec.gov.

 

Investor & Media Contacts:

 

Will Brown

Stacey Jurchison

Chief Financial Officer

Sr. Dir, Investor Relations

Phone: 240-654-1450

Phone: 410-474-8200

wbrown@altimmune.com

sjurchison@altimmune.com

 


 

 

ALTIMMUNE, INC.

CONSOLIDATED BALANCE SHEETS

 

 

 

 

March 31, 2021

 

 

December 31, 2020

 

 

 

(unaudited)

 

 

 

 

 

ASSETS

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

149,932,387

 

 

$

115,917,807

 

Restricted cash

 

 

34,174

 

 

 

34,174

 

Total cash, cash equivalents and restricted cash

 

 

149,966,561

 

 

 

115,951,981

 

Short-term investments

 

 

76,574,768

 

 

 

100,005,558

 

Accounts receivable

 

 

4,801,428

 

 

 

4,610,202

 

Tax refund receivable

 

 

7,898,067

 

 

 

7,762,793

 

Prepaid expenses and other current assets

 

 

5,950,999

 

 

 

1,926,675

 

Total current assets

 

 

245,191,823

 

 

 

230,257,209

 

Property and equipment, net

 

 

5,198,052

 

 

 

1,056,920

 

Right of use asset

 

 

866,336

 

 

 

903,825

 

Intangible assets, net

 

 

12,879,247

 

 

 

12,823,846

 

Other assets

 

 

115,300

 

 

 

73,413

 

Total assets

 

$

264,250,758

 

 

$

245,115,213

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

418,243

 

 

$

612,293

 

Accrued expenses and other current liabilities

 

 

9,405,649

 

 

 

11,408,154

 

Total current liabilities

 

 

9,823,892

 

 

 

12,020,447

 

Contingent consideration

 

 

6,270,000

 

 

 

5,390,000

 

Other long-term liabilities

 

 

1,719,438

 

 

 

1,828,443

 

Total liabilities

 

 

17,813,330

 

 

 

19,238,890

 

Commitments and contingencies (Note 16)

 

 

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

 

 

Common stock, $0.0001 par value; 200,000,000 shares authorized;

38,257,180 and 37,142,946 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively

 

 

3,810

 

 

 

3,697

 

Additional paid-in capital

 

 

462,417,706

 

 

 

417,337,742

 

Accumulated deficit

 

 

(210,944,707

)

 

 

(186,420,599

)

Accumulated other comprehensive loss, net

 

 

(5,039,381

)

 

 

(5,044,517

)

Total stockholders’ equity

 

 

246,437,428

 

 

 

225,876,323

 

Total liabilities and stockholders’ equity

 

$

264,250,758

 

 

$

245,115,213

 

 



 

 

 

ALTIMMUNE, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

 

 

 

For the Three Months Ended

March 31,

 

 

 

2021

 

 

2020

 

Revenues

 

$

837,516

 

 

$

2,212,694

 

Operating expenses:

 

 

 

 

 

 

 

 

Research and development

 

 

11,877,900

 

 

 

7,187,531

 

General and administrative

 

 

3,821,420

 

 

 

2,331,917

 

Total operating expenses

 

 

15,699,320

 

 

 

9,519,448

 

Loss from operations

 

 

(14,861,804

)

 

 

(7,306,754

)

Other income (expense):

 

 

 

 

 

 

 

 

Interest expense

 

 

(11,671

)

 

 

(1,885

)

Interest income

 

 

42,499

 

 

 

151,569

 

Other (expense) income, net

 

 

(33,132

)

 

 

25,542

 

Total other (expense) income, net

 

 

(2,304

)

 

 

175,226

 

Net loss before income tax benefit

 

 

(14,864,108

)

 

 

(7,131,528

)

Income tax benefit

 

 

 

 

 

3,245,879

 

Net loss

 

 

(14,864,108

)

 

 

(3,885,649

)

Other comprehensive income (loss) – unrealized gain (loss) on investments

 

 

5,136

 

 

 

(32,435

)

Comprehensive loss

 

$

(14,858,972

)

 

$

(3,918,084

)

Net loss per share, basic and diluted

 

$

(0.38

)

 

$

(0.26

)

Weighted-average common shares outstanding, basic and diluted

 

 

38,914,990

 

 

 

15,110,585

 

 

 



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings